Skip to content
lifestyle.hubspotes.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Nanobiotix S.A.
NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer
September 14, 2026
NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026
September 11, 2026
NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 9, 2026
Voting Rights and Shares Capital of the Company
August 25, 2026
Voting Rights and Shares Capital of the Company
July 30, 2026
Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study
May 4, 2026
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
April 20, 2026
Voting Rights and Shares Capital of the Company
April 7, 2026
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results
April 1, 2026
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
March 30, 2026
1
2
Next Page
→